Keudell Morrison Wealth Management Takes $596,000 Position in Sanofi $SNY

Keudell Morrison Wealth Management acquired a new position in shares of Sanofi (NASDAQ:SNY) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 12,308 shares of the company’s stock, valued at approximately $596,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Axxcess Wealth Management LLC boosted its position in shares of Sanofi by 4.0% during the 4th quarter. Axxcess Wealth Management LLC now owns 10,818 shares of the company’s stock worth $524,000 after acquiring an additional 415 shares in the last quarter. Pzena Investment Management LLC raised its position in shares of Sanofi by 76.3% during the 4th quarter. Pzena Investment Management LLC now owns 11,749 shares of the company’s stock worth $569,000 after acquiring an additional 5,083 shares in the last quarter. Newport Trust Company LLC acquired a new stake in shares of Sanofi during the 4th quarter worth about $37,421,000. Global Retirement Partners LLC lifted its stake in Sanofi by 83.8% during the fourth quarter. Global Retirement Partners LLC now owns 21,385 shares of the company’s stock worth $1,036,000 after purchasing an additional 9,748 shares during the last quarter. Finally, Larson Financial Group LLC boosted its holdings in Sanofi by 48.9% in the fourth quarter. Larson Financial Group LLC now owns 810 shares of the company’s stock valued at $39,000 after purchasing an additional 266 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Stock Up 0.6%

SNY stock opened at $44.92 on Friday. The company has a market cap of $109.56 billion, a price-to-earnings ratio of 12.55, a price-to-earnings-growth ratio of 1.10 and a beta of 0.35. The company has a fifty day moving average price of $45.58 and a 200 day moving average price of $47.25. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. Sanofi has a 12 month low of $42.33 and a 12 month high of $53.03.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be paid a dividend of $2.4225 per share. This represents a dividend yield of 559.0%. This is a positive change from Sanofi’s previous annual dividend of $2.04. The ex-dividend date is Monday, May 4th. Sanofi’s payout ratio is currently 49.16%.

Analyst Ratings Changes

Several brokerages have commented on SNY. BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Monday, April 20th. Wall Street Zen cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Morgan Stanley set a $52.00 price target on shares of Sanofi in a research note on Friday, May 1st. Finally, Argus upgraded shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $51.00.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.